Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
|Videos|April 24, 2014
The Utility of CAPTEM in Chemo-Resistant Neuroendocrine Tumors
Author(s)Robert L. Fine, MD
Robert L. Fine, MD, from Columbia University, comments on the utility of CAPTEM in chemotherapy-resistant neuroendocrine tumors.
Advertisement
Clinical Pearls
Robert L. Fine, MD, associate professor of medicine, Herbert Irving, director, Experimental Therapeutics, medical oncology director, Pancreas Center, Columbia University, comments on the utility of CAPTEM in chemotherapy-resistant neuroendocrine tumors.
- In a phase II trial, CAPTEM elicited a response rate of 45% and a stable disease rate of 52%.
- Carcinoids, which represent the majority of all neuroendocrine tumors and typically have a response rate of 0-4%, showed a 45% response rate in this study.
- CAPTEM was well tolerated: Just 10-15% of patients experienced grade 3 toxicities.
Advertisement
Related to this article
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies, yet gaps persist, and research funding uncertainty threatens future gains.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
5